Hepatomegaly Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Clinical Trials

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Conditions:   BCR-JAK2 Fusion Protein Expression;   Blasts 20 Percent or Less of Peripheral Blood White Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Peripheral Blood White Cells;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Eosinophilia;   Hepatomegaly;   Hypereosinophilic Syndrome;   JAK2 Gene Mutation;   Splenomegaly;   TEL-JAK2 Fusion Protein Expression Intervention:   Drug: Ruxolitinib Sponsors:   Stanford University;   Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2019 Category: Research Source Type: clinical trials

Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus
Condition:   Hepatomegaly Intervention:   Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2018 Category: Research Source Type: clinical trials